Value of M2BP in predicting in‐stent restenosis in patients after coronary drug‐eluting stent implantation.

Objective: We evaluated the association between plasma levels of mac‐2 binding protein (M2BP) with the risk of in‐stent restenosis (ISR) after percutaneous coronary intervention (PCI). Methods: Plasma M2BP levels were compared between 258 patients who experienced ISR at 12‐months post‐PCI and 258 patients, matched for age and sex, without angiographic evidence of ISR. Results: The plasma M2BP level was significantly higher in the ISR than in the non‐ISR group. On multivariate analysis, adjusted for potential clinical, biochemical, and angiography characteristics, M2BP remained as an independent significant predictor of ISR. Conclusions: M2BP may be an important predictive biomarker of ISR and may be useful in identifying at‐risk patients. Summary Points: In‐stent restenosis (ISR) remains a major problem after percutaneous coronary intervention (PCI) and the underlying mechanisms have not yet been fully elucidated.Plasma Mac‐2 binding protein (M2BP) levels were evaluated in 258 patients who experience ISR and 258 patients without angiographic evidence of ISR at approximately 12 months after PCI.Notably, plasma M2BP levels were significantly higher patients with (12.91 ± 5.17 μg/ml) than without (10.07 ± 4.86 μg/ml) ISR (p =.001).Compared with patients with the lowest tertile of M2BP, patients in the mid and highest tertiles of plasma M2BP had a more than 1.3‐fold and 1.8‐fold increased risk of ISR, respectively (both p <.001).Multivariate logistic regression analysis revealed that, after adjustment for potential clinical factors, elevated plasma M2BP remained an independent predictor of ISR, either as a continuous or as a categorical variable (both p <.001).M2BP is an important predictive biomarker of ISR and a mediator of growth and migration in vascular smooth muscle cells.Plasma M2BP assessment may be useful in identifying patients who are at high risk of ISR. [ABSTRACT FROM AUTHOR]